In vitro diagnostics provider bioMérieux has collaborated with Oxford Nanopore Technologies for the development of novel infectious disease diagnostic products.
The companies will work together to offer access to nanopore-based clinical research and in vitro diagnostic (IVD) solutions to improve patient care.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Nanopore-based sequencing is a novel technology that can be used to analyse long DNA or RNA fragments in real time. It helps monitor changes in an electrical current when nucleic acid passes through a protein nanopore.
The resulting signal will then be decoded using algorithms to offer the specific DNA or RNA sequence.
The technology’s real-time, scalable features enable the rapid and cost-effective detection of multiple pathogens in clinical samples.
Oxford Nanopore Technologies CEO Gordon Sanghera said: “We are pleased to partner with bioMérieux’s IVD expertise to add powerful new tools for the fight against infectious disease.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“By offering rapid and accurate identification of pathogens and associated antimicrobial resistance at scale, we hope to better equip the specialists for whom speed and access to comprehensive data are key.”
The companies will initially develop a test to determine antibiotic resistance of tuberculosis and an assay for the detection of pathogens in normally sterile clinical samples.
They will also test Oxford Nanopore’s sequencing platform with bioMérieux’s EPISEQCS software application for monitoring infection outbreaks in patient-care settings.
bioMérieux chairman and CEO Alexandre Mérieu said: “We are excited to enter into a research partnership with Oxford Nanopore in the field of infectious diseases.
“New technologies such as sequencing hold promise to improve diagnostics and patient care; our teams will collaborate in this direction.”
